247. Phase I Study of Second Generation Chimeric Antigen Receptor-Engineered T Cells Targeting IL13Rα2 for the Treatment of Glioblastoma

Molecular Therapy - United States
doi 10.1016/s1525-0016(16)33056-8
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Chimeric Antigen Receptor T Cells for the Treatment of Lymphoma

Annals of Lymphoma
2017English

768. Improved Chimeric Antigen Receptor-Engineered T Cells for the Treatment of Refractory and Relapsed Leukemia

Molecular Therapy
Molecular MedicineMolecular BiologyPharmacologyMedicineGeneticsDrug Discovery
2014English

Pre-Clinical Evaluation of CD38 Chimeric Antigen Receptor Engineered T Cells for the Treatment of Multiple Myeloma

Haematologica
Hematology
2016English

Chimeric Antigen Receptor T-Cells

Cancer Journal
Cancer ResearchOncology
2015English

Chimeric Antigen Receptor Transduced T Cells - Tuning Up for the Next Generation

International Journal of Cancer
Cancer ResearchOncology
2017English

Retargeting CD19 Chimeric Antigen Receptor T Cells via Engineered CD19-Fusion Proteins

English

Chimeric Antigen Receptor T-Cell Immunotherapy for Glioblastoma: Practical Insights for Neurosurgeons

Neurosurgical Focus
MedicineSurgeryNeurology
2018English

Clinical Chimeric Antigen Receptor‐T Cell Therapy: A New and Promising Treatment Modality for Glioblastoma

Clinical and Translational Immunology
AllergyImmunologyNursing
2019English

Development of GPC3-specific Chimeric Antigen Receptor-Engineered Natural Killer Cells for the Treatment of Hepatocellular Carcinoma

Molecular Therapy
Molecular MedicineMolecular BiologyPharmacologyMedicineGeneticsDrug Discovery
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy